pH INDEPENDANT ORAL CONTROLLED RELEASE OF VERAPAMIL HCL: SOLUBILISATION IN THE MICROENVIRONMENT USING ENTEROSOLUBLE POLYMER OR ORGANIC ACID

机译：维拉帕米盐酸盐的pH依赖性口服控制释放：使用可溶性聚合物或有机酸可在微环境中溶解

获取原文

页面导航

摘要
著录项
相似文献
相关主题

摘要

Development of oral controlled release (CR) systems of verapamil HC1, releasing the drug uniformly in a pH independent fashion, were studied.

机译：研究了维拉帕米HCl的口服控释（CR）系统的开发，该系统以不依赖pH的方式均匀释放药物。

著录项

来源
《International symposium on controlled release of bioactive materials;Consumer diversified products conference》|2001年|p.774-775|共2页
会议地点
作者
G. Ramprakash; M.S. Nagarsenker;
展开▼
作者单位

展开▼
会议组织
原文格式 PDF
正文语种
中图分类基础医学;
关键词
verapamil HC1; eudragit L100; coevaporate; succinic acid; pH independent release;

机译：维拉帕米HCl; eudragit L100;共蒸发琥珀酸pH独立释放;

相似文献

外文文献
中文文献
专利

1. Basic drug--enterosoluble polymer coevaporates: development of oral controlled release systems. [J] . Govindarajan R, Nagarsenker MS Drug development and industrial pharmacy . 2004,第8期

机译：基础药物-水溶性聚合物共蒸发：口服控释系统的开发。
2. Controlled release of acidic drugs in compendial and physiological hydrogen carbonate buffer from polymer blend-coated oral solid dosage forms [J] . Wulff R., Rappen G. -M., Koziolek M., European journal of pharmaceutical sciences . 2015,第Null期

机译：从聚合物共混物包衣的口服固体剂型中，在药典和生理用碳酸氢盐缓冲液中控制酸性药物的释放
3. Aqueous-Based Cellulose Acetate Butyrate Dispersion: Screening of Process and Formulation Variables to Obtain Verapamil HCl-Controlled Release Beads [J] . Siva Vaithiyalingam, Indra K.Reddy, Mansoor A.Khan, Particulate Science and Technology: An International Journal . 2001,第2期

机译：基于水的醋酸丁酸纤维素分散体：筛选过程和配方变量以获得维拉帕米HCl控制释放珠
4. Investigation of Moisture-Activated Granulation of Hydrophilic Polymer Blends in Verapamil HCl ExtendedRelease Matrices [C] . Lawrence M. Martin, Sandip B. Tiwari, Ali Rajabi-Siahboomi Annual meeting exposition of the Controlled Release Society . 2009

机译：维拉帕米HCl扩展释放基质中亲水性聚合物共混物的水分活化制粒研究
5. Development of novel spray coated soft elastic gelatin capsule sustained release formulations of nifedipine, bioavailability and bioequivalence of verapamil HCL controlled release formulations, pharmacokinetics of terbinafine after single oral doses in raptors. [D] . Fahmy, Sahar Abd El-Sattar. 2004

机译：硝苯地平新型喷雾包衣的软弹性明胶胶囊缓释制剂的开发，维拉帕米盐酸盐控释制剂的生物利用度和生物等效性，在猛禽中单次口服剂量后特比萘芬的药代动力学。
6. Polymer Percolation Threshold in HPMC Extended Release Formulation of Carbamazepine and Verapamil HCl [O] . Tamara Gonçalves-Araújo, Ali R. Rajabi-Siahboomi, Isidoro Caraballo 2010

机译：卡马西平和维拉帕米HCl的HPMC缓释制剂中的聚合物渗滤阈值
7. Evaluation of the effect of oral verapamil on clinical outcome and angiographic restenosis after percutaneous coronary intervention The randomized, double-blind, placebo-controlled, multicenter verapamil slow-release for prevention of cardiovascular events after angioplasty (VESPA) trial [O] . Bestehorn Hans-Peter, Neumann Franz-Josef, Büttner Heinz Joachim, 2004

机译：经皮冠状动脉介入治疗后口服维拉帕米对临床结局和血管造影再狭窄的作用评估随机，双盲，安慰剂对照，多中心维拉帕米缓释用于预防血管成形术（VESPA）后的心血管事件
8. Controlled Activity Polymers: Acrylic Acid Copolymers of b-Naphthyl Acrylate, 2-Acrylamido(b-Naphthyl)Valerate, 3-Acrylamido-3-Methyl (b-Naphthyl)Butanoate, and 6-Acrylamido(b-Naphthyl)-Caproate: Release Behavior [R] . Boudreaux, C., Bunyard, C., McCormick, C. L. 1994

机译：受控活性聚合物：b-萘基丙烯酸酯，2-丙烯酰胺基（b-萘基）戊酸酯，3-丙烯酰胺基-3-甲基（b-萘基）丁酸酯和6-丙烯酰胺基（b-萘基） - 己酸酯的丙烯酸共聚物：释放行为

pH INDEPENDANT ORAL CONTROLLED RELEASE OF VERAPAMIL HCL: SOLUBILISATION IN THE MICROENVIRONMENT USING ENTEROSOLUBLE POLYMER OR ORGANIC ACID

摘要

著录项

相似文献

相关主题

期刊订阅